The detection of CMV pp65 and IE1 in glioblastoma multiforme.
Glioblastoma multiforme (GBM) is a highly lethal brain tumor affecting children and adults, with the majority of affected individuals dying from their disease by 2 years following diagnosis. Other groups have reported the association of cytomegalovirus (CMV) with GBM, and we sought to confirm these findings in a large series of patients with primary GBM from our institution. Immunohistochemical analysis of paraffin embedded tissue sections was performed on 49 newly diagnosed GBM tumors, the largest series reported to date. We confirmed the presence of CMV pp65 on 25/49 (51%) and of IE1 on 8/49 (16%) of these tumors. While pp65 and IE1 are generally found in the nucleus of cells that are permissibly infected by CMV, GBM in this series had mostly cytoplasmic staining, with only 16% having nuclear staining for one or both of these antigens. We infected GBM cell lines with a laboratory strain of CMV, and found that most of the staining was cytoplasmic, with some perinuclear localization of IE1. To test the potential for CMV infected GBM cells to be recognized by CMV pp65 and IE1 specific cytotoxic T lymphocytes (CTL), we used CMV infected GBM cell lines in cytotoxicity assays with human leukocyte antigen partially matched CMV CTL. Lysis of CMV infected GBM tumor cells was accentuated by pre-treating these cell lines with either the demethylating agent decitabine or interferon-γ, both of which were shown to increase MHC Class I and II expression on tumor cells in vitro. These studies confirm the presence of CMV pp65 or IE1 on approximately half of GBM, with the possibility that CMV positive tumor cells can be recognized by CMV pp65/IE1 specific T cells.
Lucas
Kenneth G
KG
Department of Pediatrics, Penn State Hershey Children's Hospital, 500 University Drive, Room C7830, Hershey, PA 17033, USA. klucas@psu.edu
Bao
Lei
L
Bruggeman
Richard
R
Dunham
Kimberly
K
Specht
Charles
C
D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000276:immunology / Q000821:virology*; D002469:Cell Separation; D003586:Cytomegalovirus Infections / Q000276:immunology; D005260:Female; D005434:Flow Cytometry; D005455:Fluorescent Antibody Technique; D005909:Glioblastoma / Q000276:immunology / Q000821:virology*; D006801:Humans; D017874:Immediate-Early Proteins / Q000032:analysis / Q000276:immunology*; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D010750:Phosphoproteins / Q000032:analysis / Q000276:immunology*; D014763:Viral Matrix Proteins / Q000032:analysis / Q000276:immunology*
C088645:IE1 protein, cytomegalovirus; D017874:Immediate-Early Proteins; D010750:Phosphoproteins; D014763:Viral Matrix Proteins; C065418:cytomegalovirus matrix protein 65kDa
Curr Oncol Rep. 2003 Sep;5(5):372-9
12895387
J Natl Cancer Inst. 1986 Feb;76(2):223-8
3080635
Anticancer Res. 2000 Jan-Feb;20(1C):605-10
10769703
FEMS Microbiol Rev. 2004 Feb;28(1):59-77
14975530
J Neurooncol. 2007 Jan;81(2):139-48
17004103
J Biol Chem. 1996 Feb 16;271(7):3534-40
8631958
J Virol. 2007 Oct;81(19):10424-36
17652378
Neurosurgery. 1991 Jan;28(1):16-23
1994273
J Immunol. 2000 Oct 1;165(7):4105-11
11034422
J Neurosurg. 2004 Feb;100(2):310-9
15086239
J Immunol Methods. 2006 Mar 20;310(1-2):40-52
16469329
J Virol. 1997 Nov;71(11):8176-85
9343168
Neuro Oncol. 2008 Feb;10(1):10-8
17951512
Biol Blood Marrow Transplant. 2008 Oct;14(10):1156-1162
18804046
Science. 1998 Apr 10;280(5361):248-53
9535648
Mod Pathol. 2005 Jun;18(6):838-43
15578071
Viral Immunol. 2003;16(2):111-21
12828864
Clin Cancer Res. 2005 Aug 1;11(15):5515-25
16061868
Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):566-575
17255279
Neurosurgery. 1988 Dec;23(6):725-32
2851116
Clin Infect Dis. 2006 Nov 1;43(9):1143-51
17029132
J Interferon Cytokine Res. 2003 Jul;23(7):379-93
14511464
J Neuroimmunol. 1992 Jan;36(1):57-68
1735769
J Virol. 1988 Mar;62(3):1066-70
2828655
J Clin Apher. 2008;23(2):63-5
18181166
Acta Neuropathol. 2008 Jul;116(1):79-86
18351367
J Immunother. 2004 Sep-Oct;27(5):398-404
15314549
Immunol Rev. 2008 Apr;222:70-100
18363995
Br J Cancer. 2005 Feb 28;92(4):747-50
15700045
J Exp Med. 1999 Dec 6;190(11):1669-78
10587357
J Exp Med. 1988 Sep 1;168(3):919-31
2844952
Clin Liver Dis. 2005 May;9(2):191-211, v
15831268
J Gen Virol. 1986 Dec;67 ( Pt 12):2605-16
3025342
Neuro Oncol. 2001 Jul;3(3):152-8
11465395
Cancer Res. 2001 Feb 1;61(3):842-7
11221866
Lancet. 2002 Nov 16;360(9345):1557-63
12443594
Cancer Res. 2002 Jun 15;62(12):3347-50
12067971
EMBO J. 1994 Jun 15;13(12):2897-903
8026474
J Immunother. 2007 Jul-Aug;30(5):557-61
17589296
J Neurovirol. 2006 Apr;12(2):90-9
16798670
Int J Cancer. 2001 Oct 15;94(2):243-51
11668505
J Urol. 2003 Sep;170(3):998-1002
12913758
Proc Natl Acad Sci U S A. 1996 Sep 17;93(19):10399-404
8816812
J Neurooncol. 1998 Nov;40(2):151-60
9892097
N Engl J Med. 2008 Jul 31;359(5):539-41
18669440
J Biol Regul Homeost Agents. 2005 Jan-Jun;19(1-2):63-70
16178276
Immunol Rev. 2002 Oct;188:33-42
12445279